FDA Experts Push For Wider Anti-Overdose Drug Availability

Law360, Washington (April 12, 2012, 8:18 PM EDT) -- While experts at a U.S. Food and Drug Administration meeting Thursday advocated broader availability for a prescription painkiller overdose antidote, they emphasized the need for additional clinical trials before releasing the drug to the public, saying past data don't conform to regulatory needs.

Although local programs have already been distributing naloxone kits in 15 states and the District of Columbia, according to a Centers for Disease Control and Prevention report, qualified clinical data that could be used to support FDA approval to distribute naloxone as a prescription...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.